Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Caribou Biosciences, Inc. (CRBU) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/26/2023 8-K Termination of a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update"
07/20/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
07/14/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "CARIBOU BIOSCIENCES, INC. 19,230,769 Shares of Common Stock",
"10022-7650",
"Caribou Biosciences Announces Proposed Public Offering of Common Stock",
"Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering"
07/14/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/14/2023 8-K/A Quarterly results
07/13/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/13/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL",
"of the Private Securities Litigation Reform Act of 1995. These"
07/13/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FL1 40M 8 CR 1 DLBCL 40M 4 CR 4 DLBCL2 80M 1 CR 7 DLBCL2 80M 1 CR 8 PMBCL3 40M 2 CR 5 MCL 40M 2 CR 134 DLBCL 80M 2 CR 9 MZL 80M 4 PR 154 MCL 40M 4 CR 2 FL1 40M 2 CR 3 DLBCL 40M 2 CR 6 DLBCL 120M 2 CR 10 HGBL2 40M 1 PR 144 MCL 80M 2 PR 164 HGBL2 120M 1 PR 12 DLBCL 120M 2 SD 11 9 15"
07/10/2023 SC 13G PFIZER INC reports a 7.1% stake in CARIBOU BIOSCIENCES, INC.
07/06/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, ...
Docs: "SECURITIES PURCHASE AGREEMENT",
"VOTING AGREEMENT",
"Caribou Biosciences Announces $25 Million Equity Investment from Pfizer"
06/16/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update"
04/04/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma"
03/29/2023 8-K Quarterly results
03/29/2023 8-K Quarterly results
03/24/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
03/09/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/09/2023 10-K Annual Report for the period ended December 31, 2022
03/09/2023 8-K Quarterly results
Docs: "Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update"
02/14/2023 SC 13G/A PFM Health Sciences, LP reports a 7.3% stake in Caribou Biosciences, Inc.
02/09/2023 SC 13G/A FMR LLC reports a 2.4% stake in CARIBOU BIOSCIENCES INC
02/03/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/03/2023 SC 13G BlackRock Inc. reports a 7.7% stake in Caribou Biosciences, Inc.
12/16/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/29/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "-- RMAT and Fast Track designations follow CB-010’s durable complete responses at dose level 1 in the ANTLER Phase 1 trial --"
11/21/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma"
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
Docs: "Caribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update"
11/03/2022 8-K Quarterly results
10/18/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Caribou Biosciences Presents Case Report on Long-term Follow up of First Patient Dosed in Phase 1 ANTLER Trial at the Lymphoma, Leukemia, & Myeloma Congress 2022"
09/22/2022 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy